Demant Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Demant wird ein jährliches Gewinn- und Umsatzwachstum von 12.4% bzw. 6.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 28.1% betragen.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

15.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	22.6%
Wachstumsrate der Einnahmen	6.1%
Zukünftige Eigenkapitalrendite	28.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BATS-CHIXE:DEMANC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (DKK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	25,845	3,453	3,460	4,656	15
12/31/2025	24,035	3,075	3,148	4,202	17
12/31/2024	22,427	2,490	2,699	3,671	15
6/30/2024	22,836	2,535	2,836	3,644	N/A
3/31/2024	22,640	2,544	3,130	3,957	N/A
12/31/2023	22,443	2,552	3,424	4,270	N/A
9/30/2023	21,442	2,577	2,932	3,815	N/A
6/30/2023	20,902	2,488	2,462	3,387	N/A
3/31/2023	20,304	2,381	1,954	2,878	N/A
12/31/2022	19,705	2,274	1,445	2,369	N/A
9/30/2022	19,181	2,460	1,581	2,472	N/A
6/30/2022	18,656	2,645	1,716	2,575	N/A
3/31/2022	18,281	2,671	2,135	2,927	N/A
12/31/2021	17,905	2,696	2,553	3,279	N/A
9/30/2021	17,521	2,453	2,663	3,341	N/A
6/30/2021	17,137	2,209	2,772	3,403	N/A
3/31/2021	15,803	1,665	2,356	3,012	N/A
12/31/2020	14,469	1,121	1,940	2,621	N/A
9/30/2020	14,072	970	1,507	2,226	N/A
6/30/2020	13,674	818	1,073	1,831	N/A
3/31/2020	14,310	1,140	1,228	1,990	N/A
12/31/2019	14,946	1,462	1,383	2,149	N/A
9/30/2019	14,728	1,579	1,218	1,942	N/A
6/30/2019	14,510	1,695	1,052	1,734	N/A
3/31/2019	14,224	1,759	1,059	1,709	N/A
12/31/2018	13,937	1,823	1,065	1,683	N/A
9/30/2018	13,699	1,836	1,268	1,833	N/A
6/30/2018	13,461	1,849	1,471	1,982	N/A
3/31/2018	13,325	1,802	N/A	1,927	N/A
12/31/2017	13,189	1,754	N/A	1,872	N/A
9/30/2017	12,943	1,689	N/A	1,855	N/A
6/30/2017	12,697	1,624	N/A	1,837	N/A
3/31/2017	12,350	1,542	N/A	1,758	N/A
12/31/2016	12,002	1,459	N/A	1,679	N/A
9/30/2016	11,717	1,429	N/A	1,622	N/A
6/30/2016	11,432	1,399	N/A	1,565	N/A
3/31/2016	11,049	1,418	N/A	1,579	N/A
12/31/2015	10,665	1,436	N/A	1,592	N/A
9/30/2015	10,258	1,402	N/A	1,568	N/A
6/30/2015	9,850	1,367	N/A	1,544	N/A
3/31/2015	9,598	1,347	N/A	1,520	N/A
12/31/2014	9,346	1,326	N/A	1,495	N/A
9/30/2014	9,221	1,301	N/A	1,380	N/A
6/30/2014	9,095	1,275	N/A	1,265	N/A
3/31/2014	9,027	1,280	N/A	1,274	N/A
12/31/2013	8,959	1,285	N/A	1,282	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DEMANCDas prognostizierte Gewinnwachstum (12.4% pro Jahr) liegt über der Sparquote (2.1%).

Ertrag vs. Markt: DEMANCDie Erträge des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt UK (14.7% pro Jahr).

Hohe Wachstumserträge: DEMANCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DEMANCDie Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: DEMANCDie Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DEMANCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (28.1%)

Demant Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Demant A/S Updates Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2023

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/Sreiterated Guidance for the Year 2021

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken